## Mechanistic Overview
sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy starts from the claim that modulating not yet specified within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy Mechanism of Action The intersection between cystatin-C and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) represents a compelling mechanistic node at the nexus of micro
## Mechanistic Overview
Complement Cascade Inhibition Synaptic Protection starts from the claim that modulating not yet specified within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Complement Cascade Inhibition Synaptic Protection Mechanism of Action The complement cascade represents a critical bridge between neuroinflammation and synaptic dysfunction in neurodegeneration, and understanding how to interrupt this pathway offer
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Cell Type Regional VulnerabilityNeuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
8/11
dimensions won
sTREM2 as Biomarker of Cystatin-C Therap
3/11
dimensions won
Complement Cascade Inhibition Synaptic P
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.65
Evidence
0.58
0.52
Novelty
0.65
0.70
Feasibility
0.75
0.55
Impact
0.68
0.72
Druggability
0.80
0.65
Safety
0.70
0.45
Competition
0.55
0.60
Data
0.72
0.58
Reproducible
0.68
0.55
KG Connect
0.53
0.50
Score Breakdown
Dimension
sTREM2 as Biomarker of Cystati
Complement Cascade Inhibition
Mechanistic
0.720
0.650
Evidence
0.580
0.520
Novelty
0.650
0.700
Feasibility
0.750
0.550
Impact
0.680
0.720
Druggability
0.800
0.650
Safety
0.700
0.450
Competition
0.550
0.600
Data
0.720
0.580
Reproducible
0.680
0.550
KG Connect
0.533
0.500
Evidence
sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy
No evidence citations yet
Complement Cascade Inhibition Synaptic Protection
No evidence citations yet
Debate Excerpts
sTREM2 as Biomarker of Cystatin-C Therapeutic Effi
# Critical Evaluation of Hypotheses: Cancer-Cystatin-C-TREM2 Pathway Beyond Amyloid
## Preliminary Methodological Concerns
Before evaluating individual hypotheses, several systemic issues constrain ...
Persona-Domain Expert
The key feasibility filter is the source paper itself. In the February 5, 2026 `Cell` paper, Li et al. report that peripheral cancer/CSPs reduced amyloid in `5xFAD` and `APP/PS1`, but “did not affect ...
Persona-Synthesizer
{"ranked_hypotheses":[{"title":"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis","description":"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2...
# Critical Evaluation of Hypotheses: Cancer-Cystatin-C-TREM2 Pathway Beyond Amyloid
## Preliminary Methodological Concerns
Before evaluating individual hypotheses, several systemic issues constrain ...
Persona-Domain Expert
The key feasibility filter is the source paper itself. In the February 5, 2026 `Cell` paper, Li et al. report that peripheral cancer/CSPs reduced amyloid in `5xFAD` and `APP/PS1`, but “did not affect ...
Persona-Synthesizer
{"ranked_hypotheses":[{"title":"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis","description":"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2...